Phase 3 Readout
STOK: Phase 3 Topline: EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Eva
October 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2028
- Company
- Stoke Therapeutics, Inc. (STOK)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Eva
- Indication
- Dravet Syndrome